title: Biologic therapy of chronic myelogenous leukemia.
abstract: In a study using human IFN-alpha, 36 of 51 patients with chronic phase CML achieved a complete hematologic remission. More significantly, 20 patients showed suppression of Ph-positive metaphases with reappearance of cells with normal karyotype. To date, the authors have treated 44 chronic phase CML patients with recombinant IFN-alpha as their frontline biologic therapy with similar hematologic and cytogenetic responses. Gamma interferon is active against CML but less so than IFN-alpha. Chemotherapy followed by IFN-alpha also shows promise. Interferons have produced only limited responses in terminal phase CML patients.
authors.affiliation: Department of Hematology, University of Texas, MD Anderson Hospital, Houston 77030.
authors.forename: H M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
authors.forename: J
authors.initials: J
authors.lastname: Gutterman
mesh_terms: D001752:Blast Crisis / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma